We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

8601:TSEDaiwa Securities Group Inc. Analysis

Data as of 2026-03-13 - not real-time

HK$0.26

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Boltek Holdings (8601.HK) is trading at HK$0.26, comfortably above its 20‑day (HK$0.246) and 50‑day (HK$0.243) simple moving averages and just above the 200‑day SMA (HK$0.253), suggesting short‑term bullish momentum. However, the 14‑day RSI sits at 74, flagging an overbought condition, and the MACD line remains slightly bullish (0.0057 vs signal 0.0041) with a modest positive histogram. Volume has been trending downwards, and the 30‑day volatility is high at 26.5%, indicating a fragile price base. The stock’s trailing PE of 6.5 is dramatically lower than the industry average of 29, while the price‑to‑book of 1.39 is modest, painting a picture of relative cheapness on earnings metrics.
On the other hand, the discounted cash‑flow model values Boltek at only HK$0.174, meaning the market price is roughly 50 % above intrinsic estimates, and the dividend payout ratio exceeds 150 % of earnings, raising doubts about the sustainability of its 4.81 % yield. The company’s revenue growth is a modest 1.3 % and free cash flow is limited, though balance‑sheet strength is evident with cash of HK$40.7 M versus debt of HK$3.0 M. With a near‑zero beta (‑0.03) the stock is insulated from broader market swings, but the combination of high volatility, thin trading volumes, and sector cyclicality adds layers of risk. In summary, Boltek appears undervalued on traditional multiples yet overvalued relative to cash‑flow fundamentals, making the near‑term outlook uncertain while the long‑term case hinges on dividend policy and earnings stability.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • RSI in overbought territory (74)
  • Price near resistance level (HK$0.265)
  • Decreasing volume and high volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Low PE vs industry suggests value
  • Dividend payout unsustainable
  • Neutral technical trend

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong cash position vs low debt
  • Potential price correction toward DCF fair value
  • Stable ROE and operating margins

Key Metrics & Analysis

Financial Health

Revenue Growth1.30%
Profit Margin15.63%
P/E Ratio6.5
ROE18.71%
ROA11.22%
Debt/Equity2.00
P/B Ratio1.4
Op. Cash FlowHK$17.9M
Free Cash FlowHK$7.0M
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI74.3
SupportHK$0.23
ResistanceHK$0.26
MA 20HK$0.25
MA 50HK$0.24
MA 200HK$0.25
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueHK$0.17
GradeOvervalued
TypeValue
Dividend Yield4.81%

Risk Assessment

Beta-0.03
Volatility26.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.